Skip to content
2000
image of An Insight into the Anti-Cancer Potential of N-Heterocyclic Compounds Targeting Breast Cancer

Abstract

Breast cancer remains one of the leading causes of cancer-related deaths worldwide, so it is crucial to develop novel therapeutic agents to improve treatment outcomes. -heterocyclic compounds have garnered considerable interest due to their potential in treating breast cancer. -heterocyclic compounds have been demonstrated to interact with key molecular targets implicated in breast cancer progression, including Estrogen Receptors (ER), HER2, and the PI3K/Akt/mTOR signaling pathway.

This review explores the role of -heterocyclic compounds, including azetidine, imidazole, pyridine, quinoline, and pyrazole, in breast cancer treatment, focusing on their anticancer activity and efficacy. A total of 66 research studies from the PubMed and Google Scholar platforms were cited in the manuscript, demonstrating that -heterocyclic analogs exhibit superior anticancer activity compared to standard drugs such as doxorubicin and paclitaxel. Different patents related to derivatives and clinical trials reported in the paper confirm the anti-cancer potential of -heterocyclic compounds. The content of the paper will surely be beneficial to researchers working on the synthesis of novel -heterocycles and to those seeking to discover more anticancer agents featuring the lead -heterocyclic moiety. The selection of this sample size ensures comprehensive analytical depth, providing a representative pool for recent studies relevant to the role of -heterocyclics in Breast Cancer.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/coc/10.2174/0113852728400723251121095338
2026-02-23
2026-02-27

  • From This Site

    /content/journals/coc/10.2174/0113852728400723251121095338
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Facts C.S. Cancer Stat Facts: Female Breast Cancer. 2023 Available from: https://seer.cancer.gov/statfacts/html/breast.html
  2. Kumari P. Mishra R. Mazumder R. Mazumder A. Acyl urea compounds therapeutics and its inhibition for cancers in women: A review. Anticancer. Agents Med. Chem. 2025 25 2 86 98 10.2174/0118715206330232240913100744 39318218
    [Google Scholar]
  3. Singh A. Mishra R. Mazumder A. Breast cancer and its therapeutic targets: A comprehensive review. Chem. Biol. Drug Des. 2024 103 1 e14384 10.1111/cbdd.14384 37919259
    [Google Scholar]
  4. Almansour N.M. Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment, and role of artificial intelligence. Front. Mol. Biosci. 2022 9 836417 10.3389/fmolb.2022.836417 35145999
    [Google Scholar]
  5. Shao X. Xie N. Chen Z. Wang X. Cao W. Zheng Y. Yang H. Huang J. Chen S. Gan L. Yang X. Chen Y. Ouyang Q. Wang X. Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial. J. Transl. Int. Med. 2024 12 5 466 477 10.1515/jtim‑2024‑0022 39513033
    [Google Scholar]
  6. Sturz J.L. Boughey J.C. Lasting impacts of the COVID-19 pandemic on breast cancer diagnosis and treatment in the United States. Surg. Oncol. Clin. N. Am. 2023 32 4 811 819 10.1016/j.soc.2023.05.010 37714645
    [Google Scholar]
  7. Trayes K.P. Cokenakes S.E.H. Breast cancer treatment. Am. Fam. Physician 2021 104 2 171 178 34383430
    [Google Scholar]
  8. Zhai J. Wu Y. Ma F. Kaklamani V. Xu B. Advances in medical treatment of breast cancer in 2022. Cancer Innovation 2023 2 1 1 17 10.1002/cai2.46 38090370
    [Google Scholar]
  9. Łukasiewicz S. Czeczelewski M. Forma A. Baj J. Sitarz R. Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers 2021 13 17 4287 10.3390/cancers13174287 34503097
    [Google Scholar]
  10. BRCA gene changes: Cancer risk and genetic testing. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
  11. Park M. Kim D. Ko S. Kim A. Mo K. Yoon H. Breast cancer metastasis: Mechanisms and therapeutic implications. Int. J. Mol. Sci. 2022 23 12 6806 10.3390/ijms23126806 35743249
    [Google Scholar]
  12. Bassett L.W. Gold R.H. The evolution of mammography. AJR Am. J. Roentgenol. 1988 150 3 493 498 10.2214/ajr.150.3.493 3277343
    [Google Scholar]
  13. Feng Y. Spezia M. Huang S. Yuan C. Zeng Z. Zhang L. Ji X. Liu W. Huang B. Luo W. Liu B. Lei Y. Du S. Vuppalapati A. Luu H.H. Haydon R.C. He T.C. Ren G. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018 5 2 77 106 10.1016/j.gendis.2018.05.001 30258937
    [Google Scholar]
  14. Chen J.Q. Russo J. ERalpha-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochim. Biophys. Acta 2009 1796 2 162 175 10.1016/j.bbcan.2009.06.003 19527773
    [Google Scholar]
  15. Murugesan D.K. Rajagopal K. Vijayakumar A.R. Sundararajan G. Raman K. Byran G. Murugesan E. Gupta J.K. Kankate R.S. Nainu F. Barua R. Design and synthesis of pyrazole-substituted 9-anilinoacridine derivatives and evaluation against breast cancer. J. Biol. Regul. Homeost. Agents 2024 38 4 2845 2859
    [Google Scholar]
  16. Liang J.W. Gao Z.C. Yang L.L. Zhang W. Chen M.Z. Meng F.H. Development of acridone derivatives: Targeting c-MYC transcription in triple-negative breast cancer with inhibitory potential. Antioxidants 2023 13 1 11 10.3390/antiox13010011 38275631
    [Google Scholar]
  17. Garberová M. Potočňák I. Tvrdoňová M. Majirská M. Bago-Pilátová M. Bekešová S. Kováč A. Takáč P. Khiratkar K. Kudličková Z. Elečko J. Vilková M. Derivatives incorporating acridine, pyrrole, and thiazolidine rings as promising antitumor agents. Molecules 2023 28 18 6616 10.3390/molecules28186616 37764394
    [Google Scholar]
  18. Krochtová K. Halečková A. Janovec L. Blizniaková M. Kušnírová K. Kožurková M. Novel 3,9-disubstituted acridines with strong inhibition activity against topoisomerase I: Synthesis, biological evaluation and molecular docking study. Molecules 2023 28 3 1308 10.3390/molecules28031308 36770975
    [Google Scholar]
  19. Vilková M. Michalková R. Kello M. Sabolová D. Takáč P. Kudličková Z. Garberová M. Tvrdoňová M. Béres T. Mojžiš J. Discovery of novel acridine-chalcone hybrids with potent DNA binding and antiproliferative activity against MDA-MB-231 and MCF-7 cells. Med. Chem. Res. 2022 31 8 1323 1338 10.1007/s00044‑022‑02911‑0
    [Google Scholar]
  20. Vilková M. Hudáčová M. Palušeková N. Jendželovský R. Almáši M. Béres T. Fedoročko P. Kožurková M. Acridine-based n-acylhydrazone derivatives as potential anticancer agents: Synthesis, characterization and ctDNA/HSA spectroscopic binding properties. Molecules 2022 27 9 2883 10.3390/molecules27092883 35566236
    [Google Scholar]
  21. Wang Y. Wang C. Liu J. Sun D. Meng F. Zhang M. Aliper A. Ren F. Zhavoronkov A. Ding X. Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors. Bioorg. Med. Chem. 2024 103 117662 10.1016/j.bmc.2024.117662 38493730
    [Google Scholar]
  22. Wang S. Malebari A.M. Greene T.F. Kandwal S. Fayne D. Nathwani S.M. Zisterer D.M. Twamley B. O’Boyle N.M. Meegan M.J. Antiproliferative and tubulin-destabilising effects of 3-(prop-1-en-2-yl)azetidin-2-ones and related compounds in MCF-7 and MDA-MB-231 breast cancer cells. Pharmaceuticals 2023 16 7 1000 10.3390/ph16071000 37513912
    [Google Scholar]
  23. Kumar D. Aggarwal N. Kumar V. Kumar H. Deep A. Bibi S. Chopra H. Marwaha R.K. Alshammari A. Alharbi M. Hayee A. Synthesis, anticancer, antimicrobial and antioxidant potential of novel 4-(substituted phenyl-1,3,4-oxadiazol/thiadiazol-2-yl)-4-(4-substituted phenyl) azetidin-2-one derivatives. Pharmaceuticals 2023 16 4 517 10.3390/ph16040517 37111274
    [Google Scholar]
  24. Donarska B. Świtalska M. Wietrzyk J. Płaziński W. Mizerska-Kowalska M. Zdzisińska B. Łączkowski K.Z. Discovery of new 3, 3-diethylazetidine-2, 4-dione-based thiazoles as nanomolar human neutrophil elastase inhibitors with broad-spectrum antiproliferative activity. Int. J. Mol. Sci. 2022 23 14 7566 10.3390/ijms23147566 35886913
    [Google Scholar]
  25. Li S. Wang S. Tian B. Li N. Chen Y. Liu Y. Su W. Fan Y. Piao Y. Li J. Wang L. Zhao J. Wang S. Shi Y. Xiang R. Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid. OncoImmunology 2022 11 1 2097460 10.1080/2162402X.2022.2097460 40103016
    [Google Scholar]
  26. Jin J. Wu Y. Zhao Z. Wu Y. Zhou Y. Liu S. Sun Q. Yang G. Lin J. Nagle D.G. Qin J. Zhang Z. Chen H. Zhang W. Sun S. Luan X. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. JCI Insight 2022 7 22 e160606 10.1172/jci.insight.160606 36509291
    [Google Scholar]
  27. Yue P. Zhu Y. Brotherton-Pleiss C. Fu W. Verma N. Chen J. Nakamura K. Chen W. Chen Y. Alonso-Valenteen F. Mikhael S. Medina-Kauwe L. Kershaw K.M. Celeridad M. Pan S. Limpert A.S. Sheffler D.J. Cosford N.D.P. Shiao S.L. Tius M.A. Lopez-Tapia F. Turkson J. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo. Cancer Lett. 2022 534 215613 10.1016/j.canlet.2022.215613 35276290
    [Google Scholar]
  28. Abusharkh K.A.N. Onder F.C. Çınar V. Onder A. Sıkık M. Hamurcu Z. Ozpolat B. Ay M. Novel benzothiazole/benzothiazole thiazolidine‐2,4‐dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies. Arch. Pharm. 2024 357 12 2400504 10.1002/ardp.202400504 39318080
    [Google Scholar]
  29. Alamoudi W.M. Molecular modeling and cytotoxic activity of newly synthesized benzothiazole-thiazole conjugates. J. Saudi Chem. Soc. 2024 28 4 101897 10.1016/j.jscs.2024.101897
    [Google Scholar]
  30. Barbarossa A. Ceramella J. Carocci A. Iacopetta D. Rosato A. Limongelli F. Carrieri A. Bonofiglio D. Sinicropi M.S. Benzothiazole-phthalimide hybrids as anti-breast cancer and antimicrobial agents. Antibiotics 2023 12 12 1651 10.3390/antibiotics12121651 38136685
    [Google Scholar]
  31. Al-Sanea M.M. Hamdi A. Mohamed A.A.B. El-Shafey H.W. Moustafa M. Elgazar A.A. Eldehna W.M. Ur Rahman H. Parambi D.G.T. Elbargisy R.M. Selim S. Bukhari S.N.A. Hendawy O.M. Tawfik S.S. New benzothiazole hybrids as potential VEGFR-2 inhibitors: Design, synthesis, anticancer evaluation, and in silico study. J. Enzyme Inhib. Med. Chem. 2023 38 1 2166036 10.1080/14756366.2023.2166036 36691927
    [Google Scholar]
  32. Radwan I.T. Elwahy A.H.M. Darweesh A.F. Sharaky M. Bagato N. Khater H.F. Salem M.E. Design, synthesis, docking study, and anticancer evaluation of novel bis-thiazole derivatives linked to benzofuran or benzothiazole moieties as PI3k inhibitors and apoptosis inducers. J. Mol. Struct. 2022 1265 133454 10.1016/j.molstruc.2022.133454
    [Google Scholar]
  33. Banerjee S. Mandal M. Halder S. Karak A. Banik D. Jana K. Mahapatra A.K. An ICT-guided ratiometric naphthalene–benzothiazole-based probe for the detection of cyanide with real-time applications in human breast cancer cells. Anal. Methods 2022 14 33 3209 3217 10.1039/D2AY00898J 35943416
    [Google Scholar]
  34. Aruchamy B. Kuruburu M.G. Bovilla V.R. Madhunapantula S.V. Drago C. Benny S. Presanna A.T. Ramani P. Design, synthesis, and anti-breast cancer potential of imidazole–pyridine hybrid molecules in vitro and ehrlich ascites carcinoma growth inhibitory activity assessment in vivo. ACS Omega 2023 8 43 40287 40298 10.1021/acsomega.3c04384 37929115
    [Google Scholar]
  35. Spallarossa A. Rapetti F. Signorello M.G. Rosano C. Iervasi E. Ponassi M. Brullo C. Insights into the pharmacological activity of the imidazo−pyrazole scaffold. ChemMedChem 2023 18 17 e202300252 10.1002/cmdc.202300252 37366115
    [Google Scholar]
  36. Ravish A. Shivakumar R. Xi Z. Yang M.H. Yang J.R. Swamynayaka A. Nagaraja O. Madegowda M. Chinnathambi A. Alharbi S.A. Pandey V. Sethi G. Ahn K.S. Lobie P.E. Basappa B. De novo design of imidazopyridine-tethered pyrazolines that target phosphorylation of STAT3 in human breast cancer cells. Bioengineering 2023 10 2 159 10.3390/bioengineering10020159 36829653
    [Google Scholar]
  37. Jawad S.H. Al-Adilee K.J. Synthesis and characterization of a new 1-methyl imidazole derived ligand with its ionic complexes Pd(II) and Pt(IV) and study of biological activity as anticancer and antioxidant. Results Chem. 2022 4 100573 10.1016/j.rechem.2022.100573
    [Google Scholar]
  38. Khan M. Shah S.R. Khan F. Halim S.A. Rahman S.M. Khalid M. Khan A. Al-Harrasi A. Efficient synthesis with green chemistry approach of novel pharmacophores of imidazole-based hybrids for tumor treatment: Mechanistic insights from in situ to in silico. Cancers 2022 14 20 5079 10.3390/cancers14205079 36291864
    [Google Scholar]
  39. Yang D.L. Zhang Y.J. Lei J. Li S.Q. He L.J. Tang D.Y. Xu C. Zhang L.T. Wen J. Lin H.K. Li H. Chen Z.Z. Xu Z.G. Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer. Eur. J. Med. Chem. 2022 240 114565 10.1016/j.ejmech.2022.114565 35797901
    [Google Scholar]
  40. Baez-Gonzalez A.S. Carrazco-Carrillo J.A. Figueroa-Gonzalez G. Quin- tas-Granados, L.I.; Padilla-Benavides, T.; Reyes-Hernandez, O.D. Functional effect of indole-3 carbinol in the viability and invasive properties of cultured cancer cells. Biochem. Biophys. Rep. 2023 35 101492 10.1016/j.bbrep.2023.101492 37304131
    [Google Scholar]
  41. Gaur A. Peerzada M.N. Khan N.S. Ali I. Azam A. Synthesis and anti- cancer evaluation of novel indole-based arylsulfonylhydrazides against hu- man breast cancer cells. ACS Omega 2022 7 46 42036 42043 10.1021/acsomega.2c03908 36440122
    [Google Scholar]
  42. Bębenek E. Chrobak E. Wrześniok D. Synthesis and anti- cancer activity of indole-functionalized derivatives of betulin. Pharmaceutics 2022 14 11 2372 10.3390/pharmaceutics14112372 36365190
    [Google Scholar]
  43. Michalkova R. Kello M. Kudlickova Z. Gazdova M. Mirossay L. Mojzisova G. Mojzis J. Programmed cell death alterations mediated by synthetic indole chalcone resulted in cell cycle arrest, DNA damage, apopto- sis, and signaling pathway modulations in breast cancer model. Pharmaceutics 2022 14 3 503 10.3390/pharmaceutics14030503 35335879
    [Google Scholar]
  44. Qin J. Sun X. Ma Y. Cheng Y. Ma Q. Jing W. Qu S. Liu L. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4- b]indoles as potential treatment of triple negative breast cancer by suppress- ing PI3K/AKT/mTOR pathway. Bioorg. Med. Chem. 2022 55 116594 10.1016/j.bmc.2021.116594 34990979
    [Google Scholar]
  45. Saghiri K. Daoud I. Melkemi N. Mesli F. QSAR study, molecular docking/dynamics simulations and ADME prediction of 2-phenyl-1H-indole derivatives as potential breast cancer inhibitors. Biointerface Res. Appl. Chem. 2022 13 2 154 10.33263/BRIAC132.154
    [Google Scholar]
  46. Mekky A.E.M. Abdelbaath R.A. Abdelbaath R.A. Marie A.E. Arafa M.A. Halim E.E. Sanad S.M.H. New arene and/or heteroarene‐linked 1,3,4‐oxadiazoles: Synthesis of potential methicillin‐resistant Staphylococcus aureus and vancomycin‐resistant Enterococcus inhibitors. ChemistrySelect 2024 9 36 e202403359 10.1002/slct.202403359
    [Google Scholar]
  47. Corfu A.I. Santarem N. Luelmo S. Mazza G. Greco A. Altomare A. Ferrario G. Nasta G. Keminer O. Aldini G. Tamborini L. Basilico N. Parapini S. Gul S. Cordeiro-da-Silva A. Conti P. Borsari C. Discovery of 1,3,4-oxadiazole derivatives as broad-spectrum antiparasitic agents. ACS Infect. Dis. 2024 10 6 2222 2238 10.1021/acsinfecdis.4c00181 38717116
    [Google Scholar]
  48. Sharma V. Das R. Mehta D.K. Sharma D. Novel quinolone substituted 1, 3, 4-oxadiazole derivatives: Design, synthesis, antimicrobial and anti-inflammatory potential. Mol. Divers. 2024 29 3 1911 1928 10.1007/s11030‑024‑10949‑y 39096354
    [Google Scholar]
  49. Asad M. Karim S. Hasan S. Khan M.F. Ansari W.A. Said Y.A. Khan M.I. Saquib M. Hussain M.K. Synthesis and evaluation of 3,5-disubstituted-1,2,4-oxadiazolyl benzamides as potential anti-breast cancer agents: In vitro and in silico studies. Chem. Biodivers. 2025 22 3 e202402020 10.1002/cbdv.202402020 39495606
    [Google Scholar]
  50. Chandra S. Jaiswal S. Srivastava A. Gautam R.N. Gupta S.C. Dulare R. Bharty M.K. Anti-cancer activities based on ZnII complex of potassium 5-thiophen-2-yl-[1,3,4]-oxadiazole-2-thiolate: Synthesis, crystal structure, photoluminescence study and Hirshfeld analysis. J. Mol. Struct. 2024 1313 138697 10.1016/j.molstruc.2024.138697
    [Google Scholar]
  51. Jyothi G. Palabindela R. Narsimha S. Synthesis, anti-breast cancer, and EGFR activity of novel pyrido[2,3-d]pyrimidine-piperazine-1,2,4-oxadiazoles. Russ. J. Gen. Chem. 2024 94 6 1464 1474 10.1134/S1070363224060239
    [Google Scholar]
  52. Parameshwaraiah S. Xi Z. Ravish A. Mohan A. Shankarnaik V. Dukanya D. Basappa S. Preetham H. Periyasamy G. Gaonkar S. Lobie P. Pandey V. Basappa B. Development of an environment-friendly and electrochemical method for the synthesis of an oxadiazole drug-scaffold that targets poly(ADP-Ribose) polymerase in human breast cancer cells. Catalysts 2023 13 8 1185 10.3390/catal13081185
    [Google Scholar]
  53. Zhou M. Boulos J.C. Omer E.A. Klauck S.M. Efferth T. Modes of action of a novel c-myc inhibiting 1, 2, 4-oxadiazole derivative in leukemia and breast cancer cells. Molecules 2023 28 15 5658 10.3390/molecules28155658 37570631
    [Google Scholar]
  54. Vishwanath D. Girimanchanaika S.S. Dukanya D. Rangappa S. Yang J.R. Pandey V. Lobie P.E. Basappa B. Design and activity of novel oxadiazole-based compounds that target poly (ADP-ribose) polymerase. Molecules 2022 27 3 703 10.3390/molecules27030703 35163965
    [Google Scholar]
  55. Ashitha K.T. Lakshmi S. Anjali S. Krishna A. Prakash V. Anbumani S. Priya S. Somappa S.B. Design and discovery of carboxamide-based pyrazole conjugates with multifaceted potential against Triple-Negative Breast cancer MDA-MB-231 cells. Bioorg. Med. Chem. Lett. 2024 113 129960 10.1016/j.bmcl.2024.129960 39265894
    [Google Scholar]
  56. Al-Wahaibi L.H. Elbastawesy M.A.I. Abodya N.E. Youssif B.G.M. Bräse S. Shabaan S.N. Sayed G.H. Anwer K.E. New pyrazole/pyrimidine-based scaffolds as inhibitors of heat shock protein 90 endowed with apoptotic anti-breast cancer activity. Pharmaceuticals 2024 17 10 1284 10.3390/ph17101284 39458925
    [Google Scholar]
  57. Fadhil H.R. Raauf A.M.R. Mahdi M.F. Synthesis, characterization, preliminary molecular docking, pharmacological activity, and ADME studies of some new pyrazoline derivatives as anti-breast cancer agents. Pharmacia 2024 71 1 10 10.3897/pharmacia.71.e133015
    [Google Scholar]
  58. Borrego E.A. Guerena C.D. Bustamante A.Y.S. Gutierrez D.A. Valenzuela C.A. Betancourt A.P. Varela-Ramirez A. Aguilera R.J. A novel pyrazole exhibits potent anticancer cytotoxicity via apoptosis, cell cycle arrest, and the inhibition of tubulin polymerization in triple-negative breast cancer cells. Cells 2024 13 14 1225 10.3390/cells13141225 39056806
    [Google Scholar]
  59. Dabhade P.S. Dabhade M.P. Rathod L.S. Dhawale S.A. More S.A. Chaudhari S.Y. Mokale S.N. Novel pyrazole‐chalcone hybrids: Synthesis and computational insights against breast cancer. Chem. Biodivers. 2024 21 7 e202400015 10.1002/cbdv.202400015 38705852
    [Google Scholar]
  60. Hamd A.H. Al-Lami N. Anti-breast cancer activity of some synthesized pyrazole derivatives bearing imidazo [1, 2a] pyridine moiety. Iraqi J. Sci. 2023 64 7 3205 3217 10.24996/ijs.2023.64.7.1
    [Google Scholar]
  61. Vasu D. Do H.T. Li H. Hardy C.D. Awasthi A. Poulos T.L. Silverman R.B. Potent, selective, and membrane permeable 2-amino-4-substituted pyridine-based neuronal nitric oxide synthase inhibitors. J. Med. Chem. 2023 66 14 9934 9953 10.1021/acs.jmedchem.3c00782 37433128
    [Google Scholar]
  62. Abdelshaheed M.M. El Subbagh H.I. Tantawy M.A. Attia R.T. Youssef K.M. Fawzy I.M. Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays. RSC Advances 2023 13 23 15689 15703 10.1039/D3RA02875E 37235111
    [Google Scholar]
  63. Alharthy R.D. Rashid F. Ashraf A. Shafiq Z. Ford S. Al-Rashida M. Yaqub M. Iqbal J. Pyrazole derivatives of pyridine and naphthyridine as proapoptotic agents in cervical and breast cancer cells. Sci. Rep. 2023 13 1 5370 10.1038/s41598‑023‑32489‑5 37005457
    [Google Scholar]
  64. Georgiou M. Lougiakis N. Tenta R. Gioti K. Baritaki S. Gkaralea L.E. Deligianni E. Marakos P. Pouli N. Stellas D. Discovery of new 1,4,6-trisubstituted-1H-pyrazolo[3,4-b] pyridines with anti-tumor efficacy in mouse model of breast cancer. Pharmaceutics 2023 15 3 787 10.3390/pharmaceutics15030787 36986648
    [Google Scholar]
  65. Zailaee R.A. Zailaie S.A. Sobahy T.M. Al-Amshany Z.M. Al-Footy K.O. El-Shishtawy R.M. Synthesis and antitumorigenesis effect of novel 2-amino -3-cyano pyridine derivatives containing sulfonamide moiety against breast cancer. J. Mol. Struct. 2024 1301 137309 10.1016/j.molstruc.2023.137309
    [Google Scholar]
  66. Zaher N.H. Elhazek R.M.M. Gouda A.E. Khalil A. Elgazzar M.G. Challenging breast cancer through novel sulfonamide-pyridine hybrids: Design, synthesis, carbonic anhydrase IX inhibition and induction of apoptosis. Future Med. Chem. 2023 15 2 147 166 10.4155/fmc‑2022‑0197 36762576
    [Google Scholar]
  67. Altaher A. Adris M. Aliwaini S. Awadallah A. Morjan R. The anticancer effects of novel imidazo [1, 2-a] pyridine compounds against HCC1937 breast cancer cells. Asian Pac. J. Cancer Prev. 2022 23 9 2943 2951 10.31557/APJCP.2022.23.9.2943 36172656
    [Google Scholar]
  68. Yuan J. Narasimhachar B.C. Ravish A. Yang L. Zhang H. Wang Q. Li Z. Huang J. Wang B. Wang G. Kumar Harish K. Chinnathambi A. Govindasamy C. Madegowda M. Basappa B. Discovery of oxazine-linked pyrimidine as an inhibitor of breast cancer growth and metastasis by abrogating NF-κB activation. Front. Oncol. 2024 14 1390992 10.3389/fonc.2024.1390992 39135991
    [Google Scholar]
  69. Abd Al Moaty M.N. El Kilany Y. Awad L.F. Soliman S.M. Barakat A. Ibrahim N.A. Abu-Serie M.M. Haukka M. El-Yazbi A. Teleb M. Triggering breast cancer apoptosis via cyclin-dependent kinase inhibition and DNA damage by novel pyrimidinone and 1,2,4-triazolo [4,3-a] pyrimidinone derivatives. ACS Omega 2024 9 19 21042 21057 10.1021/acsomega.4c00466 38764636
    [Google Scholar]
  70. Ravish A. Narasimhachar B.C. Xi Z. Vishwanath D. Mohan A. Gaonkar S.L. Chandrashekara P.G. Ahn K.S. Pandey V. Lobie P.E. Basappa B. Development of piperazine oxazine-linked pyrimidines as p65 subunit binders of NF–κB in human breast cancer cells. Biomedicines 2023 11 10 2716 10.3390/biomedicines11102716 37893090
    [Google Scholar]
  71. Kim N.Y. Vishwanath D. Xi Z. Nagaraja O. Swamynayaka A. Kumar Harish K. Basappa S. Madegowda M. Pandey V. Sethi G. Lobie P.E. Ahn K.S. Basappa B. Discovery of pyrimidine- and coumarin-linked hybrid molecules as inducers of JNK phosphorylation through ROS generation in breast cancer cells. Molecules 2023 28 8 3450 10.3390/molecules28083450 37110684
    [Google Scholar]
  72. Salem M.M. Gerges M.N. Noser A.A. Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. Sci. Rep. 2022 12 1 22146 10.1038/s41598‑022‑26571‑7 36550279
    [Google Scholar]
  73. Subramani A.K. Sivaperuman A. Natarajan R. Bhandare R.R. Shaik A.B. QSAR and molecular docking studies of pyrimidine-coumarin-triazole conjugates as prospective anti-breast cancer agents. Molecules 2022 27 6 1845 10.3390/molecules27061845 35335208
    [Google Scholar]
  74. Siddiqui H. Rizvi F. Shehzad W. sharif, R.; Hassam, M.; Uddin, R.; Iqbal Choudhary, M. Quinoline sulfonates as the potent inhibitors of MDA-MB-231 and MCF-7 breast cancer cells: Synthesis, cytotoxicity, and molecular docking studies. Results Chem. 2024 10 101692 10.1016/j.rechem.2024.101692
    [Google Scholar]
  75. Srinivasa S.B. Poojary B. Kalal B.S. Brahmavara U. Vaishali D. Das A.J. Mwalingo Kalenga T. Paidikondala M. Shankar M.K. Design, synthesis and anticancer activity of Novel benzimidazole containing quinoline hybrids. Results Chem. 2024 9 101631 10.1016/j.rechem.2024.101631
    [Google Scholar]
  76. Priya M.G.R. Solomon V.R. Hemavathy N. Jeyakanthan J. Kumar D. Mahesh J. Design, synthesis, in silico, and pharmacological evaluation of novel quinoline derivatives containing substituted piperazine moieties as potential anti-breast cancer agents. Results Chem. 2024 7 101359 10.1016/j.rechem.2024.101359
    [Google Scholar]
  77. Abdelmegeed H. Abdel Ghany L.M.A. Youssef A. El-Etrawy A.A.S. Ryad N. Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking. RSC Advances 2024 14 31 22092 22112 10.1039/D4RA04371E 39005243
    [Google Scholar]
  78. Abd El-Lateef H.M. Ahmed Gaafar A.G. Alqahtani A.S. Al-Mutairi A.A. Alshaya D.S. Elsaid F.G. Fayad E. Farouk N.A. Design, synthesis, and antiproliferative screening of new quinoline derivatives bearing a cis-vinyl triamide motif as apoptosis activators and EGFR-TK inhibitors. RSC Advances 2024 14 34 24781 24790 10.1039/D4RA04915B 39114435
    [Google Scholar]
  79. Govindarao K. Srinivasan N. Suresh R. Raheja R.K. Annadurai S. Bhandare R.R. Shaik A.B. Quinoline conjugated 2-azetidinone derivatives as prospective anti-breast cancer agents: In vitro antiproliferative and anti-EGFR activities, molecular docking and in-silico drug likeliness studies. J. Saudi Chem. Soc. 2022 26 3 101471 10.1016/j.jscs.2022.101471
    [Google Scholar]
  80. Rahi V. Kaur N. Kumar S. Arora P. Recent advances in the medicinal chemistry of tetrazole as antibacterial agents: A comprehensive study. Pharmaspire 2021 13 42 53
    [Google Scholar]
  81. Khdir J.A. Aziz D. Qader I. Meena B.I. İbrahim B.M. Nano-catalytic synthesis of 5-substituted 1H tetrazole derivatives and biological applications. J. Turk. Chem. Soc. A: Chem. 2024 11 4 1495 1514 10.18596/jotcsa.1436801
    [Google Scholar]
  82. Li X. Wang X. Wang Y. Tan Y. Liu D. Zhang X. Li Y. Xu J. Discovery of tetrazole thioethers: An efficient, environmentally friendly and metal-free S-arylation using diaryliodonium salts. J. Saudi Chem. Soc. 2024 28 6 101943 10.1016/j.jscs.2024.101943
    [Google Scholar]
  83. Manwar H.Q. Al-Shuhaib Z. Hussein K.A. Synthesis and molecular docking studies of new tetrazole-acetamide derivatives as anti-cancer agent. Trop. J. Nat. Prod. Res. 2024 8 8 8093 8100 10.26538/tjnpr/v8i8.25
    [Google Scholar]
  84. Prabhu D.J. Frankling J. Steephan M. John J. Sreehari A.P. Chandrika B.B. Multicomponent reactions for the synthesis of tetrazole derivatives: Discovery and validation of a novel anticancer agent active against ER positive cancers. Results Chem. 2024 7 101470 10.1016/j.rechem.2024.101470
    [Google Scholar]
  85. Kaur K. Verma H. Gangwar P. Dhiman M. Jaitak V. Design, synthesis, in vitro and in silico evaluation of indole-based tetrazole derivatives as putative anti-breast cancer agents. RSC Med. Chem. 2024 15 4 1329 1347 10.1039/D3MD00730H 38665833
    [Google Scholar]
  86. Moreno-Perea M. Suárez-Castro A. Fraire-Soto I. Sifuentes-Padilla J.L. Gutiérrez-Hernández R. Reyes-Estrada C.A. López-Hernández Y. Cortés-García C.J. Chacón-García L. Granados-López A.J. López J.A. Proliferation, migration and invasion of breast cancer cell lines are inhibited by 1,5-disubstituted tetrazol-1,2,3-triazole hybrids through interaction with p53. Molecules 2023 28 22 7600 10.3390/molecules28227600 38005322
    [Google Scholar]
  87. Alasadi Y.K. Jumaa F.H. Mukhlif M.G. Shawkat S.M. Preparation, characterization, anti-cancer and antibacterial evaluation of new schiff base and tetrazole derivatives. Tikrit J. Pure Sci. 2023 28 2 12 19 10.25130/tjps.v28i2.1333
    [Google Scholar]
  88. Gao P. Han H. Hu S. Kang D. Ma C. Wu X. Xu Z. Novel heterocyclic derivatives useful as SHP2 inhibitors. Australian Patent No. AU2022204681C1 2024
    [Google Scholar]
  89. Bierbach U. Platinum acridine anti-cancer compounds and methods thereof. U.S. Patent No. US8906896 2014
    [Google Scholar]
  90. Dijcks F.A. Lusher S.J. Stock H.T. Veeneman G.H. N-substituted azetidine derivatives. W.O. Patent No. WO2012084711A1 2012
    [Google Scholar]
  91. Miles David Jay C. Tetrahydro-1H-pyrido[3,4-b]indole antiestrogenic drugs. Japan Patent JP7277424B2 2023
    [Google Scholar]
  92. Vankayalapati H. Sharma S. Sorna V. Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors. U.S. Patent US9556170B2 2017
    [Google Scholar]
  93. Govindan N. S. Pottairamachandra M.y Naremaddepalli S. Seethalamaiahchennarishnareddy G. 1,2,4-oxadiazole compounds as inhibitors of the CD47 signaling pathway. J.P. Patent JP7438955B2 2024
    [Google Scholar]
  94. Diego F. Domenico B. N-(3,5-dimethoxyphenyl)-N’-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazole-4-yl)quinoxaline-6-yl]ethane-1,2-diamine pharmaceutical composition. J.P. Patent JP6796588B2 2020
    [Google Scholar]
  95. Yang C. Cao L. Cheng H. Yuan K. Chen W. Min W. Wang L. CDK6 inhibitor of pyrimidine benzo six-membered ring parent nucleus and preparation method and application thereof. C.N. Patent CN113264920B 2022
    [Google Scholar]
  96. Ding Z. Chen S. Xu B. Liu Z. Lin Y. Wang R. Li F. Substituted 2-hydropyrazol derivatives for anti-cancer drugs. Patent TWI688559B 2020
    [Google Scholar]
  97. Chessari G. Johnson C. N. Barker M. Griffiths Jones C. M. Schacoste G. Bicyclic heterocyclic compounds and therapeutic uses thereof. Patent TWI649319B 2019
    [Google Scholar]
  98. Pemetrexed disodium and docetaxel in treating patients with advanced solid tumors, NCT01172028. 2015 Available from: https://clinicaltrials.gov/study/NCT01172028
  99. Pyridoxine in preventing hand-foot syndrome in patients who are receiving capecitabine for advanced colorectal cancer or breast cancer, NCT00559858 2013 Available from: https://clinicaltrials.gov/study/NCT00559858
  100. Indole-3-carbinol in preventing breast cancer in nonsmoking women who are at high risk for breast cancer, NCT00033345. 2016 Available from: https://clinicaltrials.gov/study/NCT00033345
  101. Study of 4-demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in patients with brain tumors (DM-CHOC-PEN), NCT02038218. 2020 Available from: https://clinicaltrials.gov/study/NCT02038218
  102. Jonathan W. Goldman P.S. Andrew Koustenis K.C. A study of abemaciclib (LY2835219) in participants with previously treated breast cancer that has spread (MONARCH 1), NCT02102490. 2020 Available from: https://clinicaltrials.gov/study/NCT02102490
  103. A phase 3 randomized, placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer, NCT02163694. 2025 Available from: https://clinicaltrials.gov/study/NCT02163694
  104. An open-label, multicenter, phase 1/2 study of poly(ADP-Ribose) polymerase (PARP) inhibitor E7449 as single agent in subjects with advanced solid tumors or with B-cell malignancies and in combination with temozolomide (TMZ) or with carboplatin and paclitaxel in subjects with advanced solid tumors, NCT01618136. 2023 Available from: https://clinicaltrials.gov/ study/NCT01618136
  105. Martin M. Campone M. Bondarenko I. Sakaeva D. Krishnamurthy S. Roman L. Lebedeva L. Vedovato J.C. Aapro M. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Ann. Oncol. 2018 29 5 1195 1202 10.1093/annonc/mdy063 29447329
    [Google Scholar]
  106. Selinexor & talazoparib in advanced refractory solid tumors; Advanced/ metastatic triple negative breast cancer (START) NCT05035745 Available from: https://clinicaltrials.gov/study/NCT05035745 2025
    [Google Scholar]
/content/journals/coc/10.2174/0113852728400723251121095338
Loading
An Insight into the Anti-Cancer Potential of N-Heterocyclic Compounds Targeting Breast Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0113852728400723251121095338
/content/journals/coc/10.2174/0113852728400723251121095338
/content/journals/coc/10.2174/0113852728400723251121095338
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: breast cancer ; N-heterocycles ; pyridine ; quinoline ; signaling pathways ; pyrazole

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test